PediaNotes

Thyroid Dyshormonogenesis and Dysgenesis

8 min read

Dyshormonogenesis

Overview

General Features

  • Accounts for 10-15% of permanent congenital hypothyroidism (CH).
  • Inheritance: Autosomal Recessive.
  • Pathophysiology: Impaired hormone synthesis → Decreased circulating T4/T3 → Lack of negative feedback → Increased TSH secretion → Compensatory thyroid hyperplasia (Goiter).
  • Goiter visible in utero, at birth, or later in childhood depending on severity.
  • Diagnosis established via scintigraphy, perchlorate discharge test, and biochemical markers.

Genetic Defects of Biosynthesis

Defect CategoryGeneDefective ProteinClinical & Biochemical Hallmark
Iodide TransportSLC5A5Sodium-Iodide Symporter (NIS)Absent/low radioiodine uptake in thyroid and salivary glands.
Apical TransportSLC26A4PendrinPendred syndrome: Sensorineural deafness, goiter, positive perchlorate discharge.
OrganificationTPOThyroperoxidaseSevere goiter, high TG, 40-90% perchlorate discharge, most common in Caucasians.
H2O2 GenerationDUOX2 / DUOXA2Dual Oxidase 2 / Maturation FactorVariable severity (transient to permanent CH), common in Asians.
ThyroglobulinTGThyroglobulinGoitrous CH with low/undetectable serum TG.
RecyclingIYD (DEHAL1)Iodotyrosine DeiodinaseSevere iodine deficiency, elevated urinary MIT/DIT.

Detailed Pathophysiology of Specific Defects

1. Sodium-Iodide Symporter (NIS) Defect

  • Gene: SLC5A5.
  • Mechanism: Failure to actively concentrate iodide from circulation into follicular cells.
  • Scintigraphy: Low or absent uptake of radioiodine/pertechnetate in thyroid gland. May mimic thyroid agenesis.
  • Differentiation: Absent normal salivary gland and gastric mucosa iodine uptake. Decreased saliva:serum 123I ratio confirms diagnosis.
  • Clinical: Variable onset (neonatal to childhood). May respond to massive iodide doses, but levothyroxine preferred.

2. Pendred Syndrome (SLC26A4 Defect)

  • Gene: SLC26A4 (encodes Pendrin).
  • Mechanism: Impaired apical iodide transport into colloid, leading to partial organification defect.
  • Syndromic Features: Congenital bilateral sensorineural deafness.
  • Thyroid Phenotype: Usually mild. Variable onset of goiter and hypothyroidism, heavily dependent on nutritional iodine intake.
  • Testing: Positive perchlorate discharge test 1 indicates impaired organification.

3. Thyroperoxidase (TPO) Defect

  • Gene: TPO.
  • Epidemiology: Most common dyshormonogenesis defect in Caucasian populations.
  • Mechanism: Complete or partial failure to oxidize and incorporate iodide into TG tyrosine residues, or failure to couple iodotyrosines.
  • Scintigraphy: High radioiodine uptake.
  • Testing: Hallmark is marked discharge of radioiodine (40-90%) upon administration of perchlorate1 or thiocyanate 2 hours after tracer dose. Normal individuals exhibit <10% discharge.
  • Biochemical: Markedly elevated serum TG. Severe goitrous CH.

4. H2O2 Generation Defects (DUOX2 and DUOXA2)

  • Genes: DUOX2 (Dual oxidase 2) and DUOXA2 (Maturation factor).
  • Epidemiology: Most common dyshormonogenesis cause in Asian populations.
  • Mechanism: Rate-limiting step for TG iodination impaired due to lack of local H2O2 generation at apical membrane.
  • Clinical Phenotype: Extremely variable. Ranges from life-threatening in utero goiter to permanent CH, to transient CH, to life-long euthyroidism. Variable compensation by DUOX1 postulated.

5. Thyroglobulin (TG) Synthesis Defect

  • Gene: TG.
  • Mechanism: Structural defects in TG glycoprotein. Impaired folding, defective intracellular transport, restricted access to tyrosine residues, or impaired coupling.
  • Clinical: Goitrous CH presenting in utero or at birth.
  • Biochemical: Characterized by low or undetectable serum TG levels, unlike other forms of dyshormonogenesis where TSH-stimulated TG is elevated.

6. Dehalogenase (Iodotyrosine Deiodinase) Defect

  • Gene: IYD (formerly DEHAL1).
  • Mechanism: Failure to deiodinate uncoupled MIT and DIT within follicular cell.
  • Pathophysiology: Iodotyrosines leak into circulation and are lost in urine. Leads to rapid, severe, continuous state of iodine deficiency.
  • Biochemical Hallmark: Elevated urinary excretion of MIT and DIT.
  • Clinical: Goitrous CH. Severity varies with dietary iodine intake.

DIAGNOSTIC EVALUATION OF DYSHORMONOGENESIS

1. Newborn Screening and Initial Labs

  • Screening: Detected via high TSH (>15-30 mU/L) on filter paper spot.
  • Confirmatory Serum: Elevated TSH, low Free T4 (FT4).
  • Thyroglobulin (TG): Elevated in most dyshormonogenesis (due to TSH stimulation). Low/undetectable specifically indicates TG synthesis defect or TSH receptor defect/thyroid agenesis.

2. Imaging Studies

  • Ultrasonography: Confirms presence of normally located (orthotopic) gland. Demonstrates normal size or goitrous enlargement.
  • Scintigraphy (Radionuclide Scan): 123I (preferred) or 99mTc pertechnetate.
    • Normal/High uptake: Confirms functional NIS. Points towards TPO, DUOX2, Pendrin, or TG defects.
    • Absent uptake: Indicates NIS (SLC5A5) defect, TSH-receptor blocking antibodies, or TSH-receptor mutations (despite gland presence on ultrasound).

3. Perchlorate Discharge Test

  • Administer radioiodine, measure uptake at 2 hours.
  • Administer potassium perchlorate (competitive inhibitor of NIS).
  • Rapid release (discharge) of >10% of accumulated tracer indicates organification defect (TPO, DUOX2, Pendrin). Trapped iodine remains unbound and washes out.

4. Genetic Testing

  • Confirms precise etiology.
  • Seldom alters immediate levothyroxine management but crucial for familial counseling (25% recurrence risk for autosomal recessive traits).

MANAGEMENT PRINCIPLES

  • Immediate Initiation: Levothyroxine (L-T4) therapy at 10-15 μg/kg/day to rapidly normalize FT4 and suppress TSH.
  • Goiter Reduction: Suppressive L-T4 doses minimize TSH-driven thyromegaly, preventing airway obstruction.
  • Outcome: Normal physical and intellectual development if initiated promptly.

Thyroid Dysgenesis

Overview

  • Most common cause of permanent congenital hypothyroidism (CH).
  • Accounts for 80-85% of CH cases globally; 75% of cases in India.
  • Characterized by abnormal formation of the thyroid gland during embryogenesis.
  • Typically sporadic occurrence; 1% familial incidence confers 40-fold increased risk.
  • High discordance in monozygotic twins suggests two-hit pathogenesis model (germline susceptibility combined with somatic postzygotic event).

Anatomical Subtypes

SubtypeFrequencyPathophysiology & Features
Ectopy70-75%Failure of embryonic thyroid migration from base of tongue to anterior neck. Sublingual location most common. Female:Male ratio 3:1. Cells fully differentiated; reduced total cell mass limits TSH-induced growth.
Athyreosis (Agenesis)15-33%Complete absence of thyroid tissue. True athyreosis defined by Serum Thyroglobulin (Tg) < 2 mcg/L. Apparent athyreosis (Tg ≥ 2 mcg/L) caused by complete TSH receptor inactivation or transplacental maternal blocking antibodies.
Orthotopic Hypoplasia / Hemiagenesis< 5%Small rudiments of tissue in normal position. Left lobe absence most common in hemiagenesis. May associate with DiGeorge or Williams syndrome.

Genetic & Molecular Etiology

Genetic defects in transcription factors essential for thyroid morphogenesis account for 2-5% of cases, often presenting with syndromic features.

GeneInheritanceAssociated Syndrome & Extra-thyroidal Phenotype
NKX2.1De novo / ADBrain-Lung-Thyroid Syndrome2
FOXE1/TTF2ARBamforth-Lazarus Syndrome3
PAX8AD / De novoKidney and urinary tract malformations, cysts within thyroid remnants.
GLIS3ARNeonatal diabetes, congenital glaucoma, sensorineural deafness, liver/kidney/exocrine pancreas failure.
JAG1ADAlagille Syndrome4
TSHRARApparent athyreosis; complete resistance to TSH stimulation.

Clinical Manifestations

  • Infants often completely asymptomatic at birth due to protective transplacental maternal T4 transfer.
  • Neonatal Signs: Large open anterior and posterior fontanels, macroglossia, umbilical hernia, prolonged jaundice (delayed glucuronide conjugation), hypotonia, hypothermia.
  • Infancy Symptoms: Lethargy, poor feeding, choking spells, hoarse cry, mottling of skin, constipation.
  • Late Findings (if untreated): Severe growth stunting, delayed psychomotor milestones, profound intellectual disability, myxedema, coarse/brittle hair, depressed nasal bridge.
  • Ectopic Thyroid Presentation: May present in later childhood as growing midline neck or base-of-tongue mass.

Investigations & Diagnosis

  • Newborn Screening: Hallmark finding is elevated TSH with low free T4 (FT4).
  • Radionuclide Scintigraphy (99mTc or 123I): Gold standard imaging. Demonstrates exact location of ectopic tissue or confirms complete absence of uptake (agenesis, TSHR defects, maternal blocking antibodies).
  • Neck Ultrasound: Confirms absence of normally located gland. Highly user-dependent; frequently misses ectopic glands.
  • Serum Thyroglobulin (Tg): Low or undetectable in true agenesis and TSHR defects; characteristically elevated in ectopy.
  • Bone Radiography: Absent distal femoral and proximal tibial epiphyses in term infants confirms prenatal onset of hypothyroidism.

Management & Prognosis

  • Primary Goal: Rapid restoration of euthyroidism to prevent irreversible neurodevelopmental damage and intellectual disability.
  • Pharmacotherapy: Oral Levothyroxine (L-T4) is the treatment of choice.
  • Timing & Dosing: Initiate promptly, ideally by 2 weeks of life. Starting dose: 10-15 mcg/kg/day.
  • Monitoring Targets: Maintain TSH strictly within age-specific reference ranges; target FT4 levels in upper half of normal range.
  • Surgical Intervention: Excision of sublingual/ectopic thyroid generally unnecessary; ectopic tissue typically becomes atrophic upon initiation of L-T4 suppressive therapy.
  • Genetic Counseling: Indicated for families presenting with syndromic features or established inheritance patterns.

Footnotes

  1. The perchlorate discharge test is a diagnostic procedure used to detect defects in iodide organification, often seen in conditions like Pendred syndrome. It involves administering radioactive iodine followed by potassium perchlorate; if the thyroid cannot properly “trap” and bind the iodine into proteins, the perchlorate forces the unbound iodine out, causing a significant drop (discharge) in thyroid radioactivity levels. ↩ ↩2

  2. Brain-lung-thyroid syndrome is a rare genetic disorder caused by mutations in the NKX2-1 gene, which is essential for the development of these three specific organs. It typically presents as a clinical triad of congenital hypothyroidism, infant respiratory distress syndrome, and a movement disorder known as benign hereditary chorea. Because the severity of symptoms varies, some individuals may only exhibit one or two of these features throughout their lives. ↩

  3. Bamforth-Lazarus syndrome is an extremely rare genetic condition caused by mutations in the TTF-2 (FKHL15) gene, which is critical for early organ development. It is primarily characterized by the triad of thyroid dysgenesis (often resulting in an absent or misplaced thyroid), a cleft palate, and spiky hair. Some individuals with this syndrome may also exhibit additional features like choanal atresia (blocked nasal passages) or bifid epiglottis. ↩

  4. Alagille syndrome is a complex genetic disorder, typically caused by mutations in the JAG1 gene, that leads to a shortage of bile ducts within the liver (bile duct paucity). This results in chronic liver disease and is classically associated with a specific group of features, including butterfly vertebrae, distinctive facial characteristics, heart defects (like peripheral pulmonic stenosis), and eye abnormalities (posterior embryotoxon). ↩

Backlinks

Graph View